company-logoActuate Therapeutics Inc$8.25
%
Analyst Rating: Hold

Stock Details

CEO

Daniel M. Schmitt

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

10

Address

1751 River Run, Fort Worth, TX, 76107

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Top Competitors

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Actuate Therapeutics Inc  $8.25

$0

Min Forecast(+0% )

$249.61

Avg Forecast( +0% )

$325

Max Forecast(+0%)

EPS

Revenue

Institutional Holder

Loading institutional holder data...

Congress Tracker 

    Showing 0 of 0 results

    Insider Trading of Key Employees

      Showing 0 of 0 results

      Financial News: ACTU